PM359
- Chronic Granulomatous Disease
Market cap $699M 181.9M shares (10-Q, Oct 31, 2026) × $3.84 close Nov 17, 2026
Most recent annual filing: 2026-03-03
Versatile, precise, and efficient gene editing technology platform used to develop in vivo and ex vivo genetic therapies; disease focus includes genetic liver diseases, cystic fibrosis, and CAR-T-based hematology/immunology/oncology programs
Proprietary Prime Editing gene editing platform — versatile, precise, and efficient technology capable of repairing nearly all types of genetic mutations across tissues including liver, lung, and immune cells; focus areas include liver genetic diseases (Wilson's Disease, Alpha-1 Antitrypsin Deficiency), Cystic Fibrosis, and hematology/immunology/oncology CAR-T development
Prime Editing gene editing technology platform — versatile, precise, and efficient gene editing enabling one-time curative treatments for diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Supports in vivo liver programs (Wilson disease, AATD, Cystic Fibrosis) via universal liver lipid nanoparticle delivery, and ex vivo CAR-T programs in hematology, immunology, and oncology.
Targeted full gene insertion platform enabling single super-exon insertion; non-viral, single-step editing approach for CAR-T and Cystic Fibrosis; designed to address nearly all CF patients and enable multiplex CAR-T engineering
Targets: CFTR, TRAC
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Every verdict Biotech Distilled has published on Prime Medicine, oldest first — the full history, never a selection. How calls are scored: the track record.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. No press release captured yet; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →